Infantile hemangiomas ß3-adrenoceptor overexpression is associated with nonresponse to propranolol.
Pediatr Res
; 91(1): 163-170, 2022 01.
Article
en En
| MEDLINE
| ID: mdl-33654276
ABSTRACT
BACKGROUND:
Propranolol (antagonist of ß1-/ß2-AR but minimally active against ß3-AR) is currently the first-line treatment for infantile hemangiomas (IH). Its efficacy is attributed to the blockade of ß2-AR. However, its success rate is ~60%. Considering the growing interest in the angiogenic role of ß3-ARs, we evaluated a possible relationship between ß3-AR expression and response to propranolol.METHODS:
Fifteen samples of surgical biopsies were collected from patients with IH. Three were taken precociously from infants and then successfully treated with propranolol (responder group). Twelve were taken later, from residual lesions noncompletely responsive to propranolol (nonresponder group). A morphometrical analysis of the percentage of ß1-, ß2-, and ß3-ARs positively stained area was compared between the two groups.RESULTS:
While no difference was found in both ß1- and ß2-AR expression level, a statistically significant increase of ß3-AR positively stained area was observed in the nonresponder group.CONCLUSIONS:
Although the number of biopsies is insufficient to draw definitive conclusions, and the different ß-AR pattern may be theoretically explained by the different timing of samplings, this study suggests a possible correlation between ß3-AR expression and the reduced responsiveness to propranolol treatment. This study could pave the way for new therapeutic perspectives to manage IH. IMPACT Propranolol (unselective antagonist of ß1 and ß2-ARs) is currently the first-line treatment for IHs, with a success rate of ~60%. Its effectiveness has been attributed to its ability to block ß2-ARs. However, ß3-ARs (on which propranolol is minimally active) were significantly more expressed in hemangioma biopsies taken from patients nonresponsive to propranolol. This study suggests a possible role of ß3-ARs in hemangioma pathogenesis and a possible new therapeutic target.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Propranolol
/
Antagonistas Adrenérgicos beta
/
Receptores Adrenérgicos beta 3
/
Hemangioma
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
/
Infant
Idioma:
En
Año:
2022
Tipo del documento:
Article